LivaNova (LIVN) Total Non-Current Liabilities (2015 - 2026)
LivaNova (LIVN) reported Total Non-Current Liabilities of $1.3 billion for Q1 2026, down 15.33% on a YoY basis from $1.5 billion in Q1 2025, and down 8.31% sequentially from $1.4 billion in Q4 2025.
LivaNova (LIVN) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
LivaNova (LIVN) has 12 years of Total Non-Current Liabilities data on file, last reported at $1.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 15.33% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 15.33% YoY), and the FY2025 full-year result was $1.4 billion, up 19.48% from the prior year.
- Total Non-Current Liabilities fell to $1.3 billion in Q1 2026, from $1.4 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.5 billion in Q1 2025 to a low of $1.0 billion in Q4 2022.
- A 5-year average of $1.2 billion and a median of $1.1 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities declined 20.01% in 2022 and surged 30.36% in 2025, its largest moves.
- Tracing LIVN's Total Non-Current Liabilities over 5 years: stood at $1.0 billion in 2022, then climbed by 6.9% to $1.1 billion in 2023, then advanced by 6.59% to $1.1 billion in 2024, then advanced by 19.48% to $1.4 billion in 2025, then declined by 8.31% to $1.3 billion in 2026.
- Business Quant data shows LIVN's Total Non-Current Liabilities at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | LivaNova | 4.30 Bn | 3.76 Bn | 243.75 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.25 Bn |
| Dec 31, 2025 | 1.36 Bn |
| Sep 30, 2025 | 1.34 Bn |
| Jun 30, 2025 | 1.34 Bn |
| Mar 31, 2025 | 1.48 Bn |
| Dec 31, 2024 | 1.14 Bn |
| Sep 30, 2024 | 1.16 Bn |
| Jun 30, 2024 | 1.13 Bn |
| Mar 31, 2024 | 1.13 Bn |
| Dec 31, 2023 | 1.07 Bn |
| Sep 30, 2023 | 1.06 Bn |
| Jun 30, 2023 | 1.01 Bn |
| Mar 31, 2023 | 1.02 Bn |
| Dec 31, 2022 | 1.00 Bn |
| Sep 30, 2022 | 1.02 Bn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 1.08 Bn |
| Dec 31, 2021 | 819.48 Mn |
| Sep 30, 2021 | 786.83 Mn |
| Jun 30, 2021 | 1.26 Bn |